Cardiovascular risk and renal transplantation:: Post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study

被引:105
作者
Jardine, AG
Fellström, B
Logan, JO
Cole, E
Nyberg, G
Grönhagen-Riska, C
Madsen, S
Neumayer, HH
Maes, B
Ambühl, P
Olsson, AG
Pedersen, T
Holdaas, H
机构
[1] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[2] Univ Hosp, Uppsala, Sweden
[3] Sahlgrens Univ Hosp, Gothenburg, Sweden
[4] Univ Hosp, Linkoping, Sweden
[5] Novartis, Basel, Switzerland
[6] Univ Hosp, Zurich, Switzerland
[7] Toronto Gen Hosp, Toronto, ON, Canada
[8] Univ Hosp, Helsinki, Finland
[9] Skejby Hosp, Aarhus, Denmark
[10] Univ Klinikum Charite, Berlin, Germany
[11] Univ Hosp, Louvain, Belgium
[12] Ullevaal Univ Hosp, Oslo, Norway
[13] Rikshosp Univ Hosp, Oslo, Norway
关键词
cardiovascular risk; renal disease; transplantation;
D O I
10.1053/j.ajkd.2005.05.014
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Renal transplantation is associated with an increased risk for premature cardiovascular disease. We analyzed the data in the placebo arm of Assessment of Lescol in Renal Transplantation (ALERT) to improve our understanding of the relationship between cardiovascular risk factors and outcomes in this unique population. Methods: We performed Cox survival analysis for myocardial infarction, cardiac death, and noncardiac death in 1,052 patients recruited to the placebo arm of ALERT. These subjects were aged 30 to 75 years, had stable graft function at least 6 months after transplantation, had a serum total cholesterol level between 155 and 348 mg/dL (4 and 9 mmol/L), and were receiving cyclosporine-based immunosuppression. Results: The results confirm previous studies. In multivarlate analysis, preexisting coronary heart disease (hazard ratio [HR], 3.69; P < 0.001), total cholesterol level (HR, 1.55 per 50 mg/dL; P = 0.0045), and prior acute rejection (HR, 2.36; P = 0.0023) were independent risk factors. Conversely, independent risk factors for cardiac death were age (HR, 1.58 per decade; P = 0.0033), diabetes (HR, 3.35; P = 0.0002), ST-T changes on the ECG (HR, 3.17; P = 0.0004), and serum creatinine level (HR, 2.65 per milligram per deciliter; P < 0.0001). Conclusion: This analysis confirms that renal transplant recipients share risk factors for myocardial infarction and cardiac death with the general population. However, the pattern of risk factors and their relationship with outcomes is atypical, highlighting the unique nature of cardiovascular risk in transplant recipients.
引用
收藏
页码:529 / 536
页数:8
相关论文
共 24 条
[1]   Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression [J].
Abbott, KC ;
Yuan, CM ;
Taylor, AJ ;
Cruess, DF ;
Agodoa, LYC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09) :2358-2365
[2]   Graft loss and acute coronary syndromes after renal transplantation in the United States [J].
Abbott, KC ;
Bucci, JR ;
Cruess, D ;
Taylor, AJ ;
Agodoa, LYC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (10) :2560-2569
[3]   Premature cardiovascular disease in chronic renal failure [J].
Baigent, C ;
Burbury, K ;
Wheeler, D .
LANCET, 2000, 356 (9224) :147-152
[4]   Cancer after renal transplantation: The next challenge [J].
Chapman, JR ;
Webster, AC .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :841-842
[5]   Risk factors for reaching renal Endpoints in the Assessment of Lescol in Renal Transplantation (ALERT) trial [J].
Fellström, B ;
Holdaas, H ;
Jardine, AG ;
Nyberg, G ;
Grönhagen-Riska, C ;
Madsen, S ;
Neumayer, HH ;
Cole, E ;
Maes, B ;
Ambühl, P ;
Olsson, AG ;
Staffler, B ;
Pedersen, TR .
TRANSPLANTATION, 2005, 79 (02) :205-212
[6]   Arterial stiffening and vascular calcifications in end-stage renal disease [J].
Guérin, AP ;
London, GM ;
Marchais, SJ ;
Metivier, F .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (07) :1014-1021
[7]   Effect of fluvastatin on cardiac outcomes in renal transplant recipients:: a multicentre, randomised, placebo-controlled trial [J].
Holdaas, H ;
Fellström, B ;
Jardine, AG ;
Holme, I ;
Nyberg, G ;
Fauchald, P ;
Grönhagen-Riska, C ;
Madsen, S ;
Neumayer, HH ;
Cole, E ;
Maes, B ;
Ambühl, P ;
Olsson, AG ;
Hartmann, A ;
Solbu, DO ;
Pedersen, TR .
LANCET, 2003, 361 (9374) :2024-2031
[8]   Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients:: Post-hoc subgroup analyses of the ALERT study [J].
Jardine, AG ;
Holdaas, H ;
Fellström, B ;
Cole, E ;
Nyberg, G ;
Grönhagen-Riska, C ;
Madsen, S ;
Neumayer, HH ;
Maes, B ;
Ambühl, P ;
Olsson, AG ;
Holme, I ;
Fauchald, P ;
Gimpelwicz, C ;
Pedersen, TR .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :988-995
[9]  
Kasiske BL, 2000, J AM SOC NEPHROL, V11, P753, DOI 10.1681/ASN.V114753
[10]  
Kasiske BL, 1996, J AM SOC NEPHROL, V7, P158